Salvage radiation therapy

RADIATION2 trials

Sponsors

Andrew J. Armstrong, MD, Asan Medical Center

Conditions

Biochemical RecurrenceDose EscalationHypofractionationProstate CancerQuality of LifeRadiationRadiation ToxicitySurvival

Phase 2

A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)

CompletedNCT03311555

Andrew J. Armstrong, MDProstate Cancer

Start: 2018-03-28End: 2022-12-22Updated: 2024-03-19

Unknown Phase

Salvage Hypofractionated Accelerated Versus Standard Radiotherapy for Biochemical Failure After Prostatectomy

RecruitingNCT03920033

Asan Medical CenterBiochemical Recurrence, Dose Escalation, Hypofractionation +5

Start: 2019-05-01End: 2027-01-01Target: 288Updated: 2021-01-20

Related Papers

Primary analysis of STARTAR: A phase 2 salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP).

Journal of Clinical Oncology2023-06-011 citations

Salvage hypofractionated accelerated versus standard radiotherapy for the treatment of biochemical recurrence after radical prostatectomy (SHARE): the protocol of a prospective, randomized, open-label, superiority, multi-institutional trial

Trials2021-10-212 citations

Interim analysis of STARTAR: A phase II salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP).

Journal of Clinical Oncology2021-02-20

A phase II Salvage Trial of AR Inhibition with ADT and Apalutamide with Radiation therapy followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (STARTAR).

Journal of Clinical Oncology2019-05-201 citations